This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)
by Zacks Equity Research
Alphatec Holdings (ATEC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
DexCom (DXCM) Down 11.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Stocks to Gain as Fed Chair "Blinks" on Rates
by Swarup Gupta
Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.
Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel
by Zacks Equity Research
Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel
4 Profitable Stocks Boasting Amazingly High Net Income Ratio
by Zacks Equity Research
Profitability analysis is considered one of the best possible ways to assess the prospects of a company.
Here's Why Investors Should Bet on DexCom (DXCM) Right Now
by Zacks Equity Research
DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.
DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
by Zacks Equity Research
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Alphabet Halts Glucose Lens Work to Focus on Other Projects
by Zacks Equity Research
Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.
DexCom (DXCM) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
DexCom (DXCM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
DexCom (DXCM) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 241.67% and 10.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
DexCom Launches CLARITY Mobile App, Strengthens CGM Profile
by Zacks Equity Research
DexCom (DXCM) benefits from the diabetes care space as it adopts cloud-based services for Continuous Glucose Monitoring.
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
Wearable Medical Device Boom Puts These 3 Stocks in Focus
by Nabaparna Bhattacharya
Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
DexCom (DXCM) Up 15.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 50.00% and 18.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?
by Zacks Equity Research
Strong performance by the PBM unit is likely to drive Express Scripts' (ESRX) top line in Q2. Home-delivery pharmacy care, specialty pharmacy care and drug data analysis services buoy optimism.
Will Global Industrial Unit Boost Ecolab's (ECL) Q2 Earnings?
by Zacks Equity Research
Solid performance in the Global Industrial segment is likely to drive Ecolab's (ECL) Q2 results. However, the company faces pricing pressure in the Energy segment.